Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Who May Qualify: - Age \> 18 years - male or female 1. Eligible female non-pregnant participants who are either not of child-bearing potential or willing to utilize adequate contraception during the trial 2. Males must be willing to practice abstinence or utilize adequate contraception from MB-102 dosing day to at least 7 days post dose - Participants willing to comply with study requirements - Participants who have signed an willing to sign a consent form form At least 5 participants will have a current history of retinal or choroidal vascular diseases. Who Should NOT Join This Trial: - Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of childbearing potential unwilling to utilize adequate contraception - Participation in another interventional trial within 30 days of treatment or concurrently enrolled in any other medical research study which could impact the results of the study - History of drug or alcohol abuse within the past year - History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 and fluorescein sodium or other related products (intolerance to a drug is not considered a drug allergy). - Prior history of seizures - Current visually significant cataracts or other ophthalmic conditions that would limit appropriate collection of fundus photographs - Site personnel immediately associated with the study or their immediate family members - Unable to tolerate ophthalmologic imaging - Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial (e.g. unstable medical condition including cardiovascular disease, or other conditions considered clinically significant or unstable by the Principal Investigator) - Prior enrollment and dosing in this study Always talk to your doctor about whether this trial is right for you.